Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab

AimsTo determine the level of vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) in the plasma of patients with proliferative diabetic retinopathy before and after an intravitreal injection of bevacizumab.MethodsEleven patients with type 2 diabetes and control of...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of ophthalmology Vol. 94; no. 9; pp. 1215 - 1218
Main Authors Matsuyama, K, Ogata, N, Matsuoka, M, Wada, M, Takahashi, K, Nishimura, T
Format Journal Article
LanguageEnglish
Published BMA House, Tavistock Square, London, WC1H 9JR BMJ Publishing Group Ltd 01.09.2010
BMJ Publishing Group
BMJ Publishing Group LTD
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:AimsTo determine the level of vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) in the plasma of patients with proliferative diabetic retinopathy before and after an intravitreal injection of bevacizumab.MethodsEleven patients with type 2 diabetes and control of 30 non-diabetic patients were studied. The 11 eyes of 11 patients received an injection of bevacizumab (1.25 mg). Samples of blood were collected just before the injection, and after 1 day, 7 days and 1 month. The concentrations of VEGF and PEDF in the plasma were measured by ELISA.ResultsThe VEGF concentration before the injection was 114.0 pg/ml. It was significantly reduced to 9.7 pg/ml after 1 day, to 11.7 pg/ml after 7 days and to 25.9 pg/ml even after 1 month (p<0.001, p<0.001, p<0.001, respectively). The PEDF concentration before the injection was 7.2 μg/ml. It was significantly reduced to 5.8 μg/ml after 1 day, to 5.8 μg/ml after 7 days and to 6.3 μg/ml after 1 month (p<0.001, p<0.001, p>0.05, respectively).ConclusionsThe decreased levels of blood VEGF after an intravitreal injection of bevacizumab indicate that bevacizumab enters the general circulation and may also affect the PEDF levels. Thus, we should carefully examine patients for systemic changes and the fellow eye after an intravitreal injection of bevacizumab.
Bibliography:ark:/67375/NVC-0KVCG0VP-L
href:bjophthalmol-94-1215.pdf
ArticleID:bjophthalmol156810
local:bjophthalmol;94/9/1215
istex:3DFB127723C9645F5C300CF8B910A99F6C45A8BC
PMID:20538658
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0007-1161
1468-2079
DOI:10.1136/bjo.2008.156810